Treatments for Alzheimer’s Disease
Symptoms of Alzheimer’s disease include cognitive loss, loss of short-term memory, difficulty processing information, and difficulty focusing on the task at hand. The symptoms can be treated and may even be reversed. These treatments include medications such as cholinergic drugs and monoclonal antibodies, as well as coping strategies.
Alcohol consumption
Several studies have investigated the relationship between alcohol consumption and Alzheimer’s disease. Alcoholics have been found to have higher Iba-1 levels, which are associated with an increased risk of AD. However, there is still a lot to be learned about the relationship between alcohol consumption and Alzheimer’s.
The researchers used a Mendelian randomization approach to determine whether alcohol intake could contribute to an earlier age of onset of Alzheimer’s disease. They analyzed data from the Health and Retirement Study, a biennial longitudinal survey of US adults over 50. The models adjusted for age, household wealth, educational attainment, and cognitive function at baseline. The model estimated that individuals who drank more than one standard drink a week were about twice as likely to develop AD as non-drinkers. They also found that individuals who drank moderately were at a reduced risk of developing AD.
The researchers measured alcohol use at a starting point, during the middle of the study, and at the end. They also measured the onset of mild cognitive impairment and dementia. The results indicated that alcohol consumption was associated with a faster rate of cognitive decline in AD patients. They also found that individuals with higher alcohol intake had a 66% chance of an earlier age of onset. However, this did not translate into a protective effect.
There are several limitations to the study. It was conducted as a prospective cohort study of 13,06 women aged 65. The subjects were also part of the ongoing Korean Brain Aging Study.
Traumatic brain injury
Several observational studies have reported an association between traumatic brain injury (TBI) and dementia. However, the extent of neural degeneration after TBI has not been clearly quantified.
A recent study from the University of Southern California (USC) investigated similarities between the structure of the brains of people with mild traumatic brain injury and Alzheimer’s disease. A team of researchers reviewed the literature on the topic and developed computer models to compare the two. They also examined the MRIs of the brains of 33 TBI patients and 81 healthy control participants.
The researchers found similar structures in the brains of people with mild TBI and Alzheimer’s disease. The study suggested that ways of identifying patients who may be at high risk for Alzheimer’s could be developed.
Another study found that older adults with a history of severe TBI were at an increased risk for Alzheimer’s disease. Those with a history of moderate TBI had a two to three times greater risk.
A third study found that older adults with a history of TBI were at an increased risk for dementia. However, other cognitive scores were not significantly associated with the risk of dementia.
Several studies have found a relationship between TBI and dementia, although the biological mechanism linking the two conditions is not fully understood. It is possible that a decrease in blood supply in the brain after TBI may have an adverse effect.
Variations of APOE e4
APOE4 is the strongest genetic risk factor for Alzheimer’s disease. It is also a strong risk factor for other diseases, including vascular dementia, tauopathy, and multiple sclerosis. It is also linked to poor outcomes after head injury.
Researchers analyzed data from more than 67,000 patients with AD and found that several APOE-related SNVs were associated with AD risk. The study was conducted by the Alzheimer’s Disease Genetics Consortium. It was supported by the NIH/NIA’s U01AG032984 grant and RC2AG036528 grant.
The APOE gene is responsible for transporting fats across several tissues and binds to neurons in the brain. It also plays a role in age-related macular degeneration and multiple sclerosis. It may also interact with other factors that influence the development of AD.
It has been shown that the apoE4 variant rs2075650 was associated with a lower risk of developing AD among e4 homozygotes. However, researchers are still unsure how this mutation actually protects patients.
Researchers have also found that the V236E mutation, a rare mutation, reduces the risk of developing AD. The mutation is co-inherited with the APOE3 variant and may have similar protective effects. However, the e3 allele is the most common in Europe and Asia.
Genetic information from these studies may lead to new preventions and treatments for Alzheimer’s disease. However, future studies must replicate these findings. This information may also lead to the discovery of new protective genes.
Cholinergic drugs
Medications that target the cholinergic system have been used in the treatment of Alzheimer’s disease. These drugs are used to reduce the amount of acetylcholine released from acetylcholinesterase. They have been found to improve cognitive and apathy symptoms in AD patients.
The cholinergic hypothesis suggests that the deterioration of cognitive functions in AD is caused by the progressive degeneration of cholinergic neurons in the basal forebrain. This hypothesis has been supported by a demonstration of ACh involvement in cognitive processes in healthy individuals. This hypothesis suggests that the primary concentrations of cholinergic neurons originate in the nucleus basalis. However, the mechanisms involved in the degradation of ACh in the cortex are not well understood.
The clinical manifestations of AD include memory loss, apathy, and extracellular deposits of b-amyloid. In patients with mild to moderate AD, sleep problems are common. These include insomnia and REM sleep deprivation. The severity of these sleep disorders increases as the disease progresses.
In addition to the loss of synapses, neurofibrillary tangles in the brain are thought to contribute to the loss of pyramidal neurons. The tangles are abnormally phosphorylated and contain tau. The presence of neurofibrillary tangles is associated with the loss of pyramidal neurons and may affect cognitive function.
In the present study, we used a computational model of cortical circuitry to simulate cognitive function in AD. This model included 80 pyramidal cells and 40 inhibitory interneurons. It was calibrated with clinical data and preclinical neurotransmitter receptor pharmacology.
Monoclonal antibodies
Various monoclonal antibodies have been investigated for the treatment of Alzheimer’s disease. These antibodies are designed to target specific epitopes in the amyloid beta peptide. They can be either active or passive immunotherapies. Active immunotherapies work by accelerating the clearance of the amyloid from the brain. Passive immunotherapies work by preventing the aggregation of the amyloid-b protein in the brain.
Monoclonal antibodies used in Alzheimer’s disease have been tested in phase 2 and phase 3 clinical trials. The results have been mixed. One of the most promising approaches is passive immunization with anti-Ab mAbs. The antibodies have been shown to reduce plaque deposition. However, their efficacy remains unclear.
The first human Ab immunotherapy trial used active immunization of recombinant Ab42. Unfortunately, side effects prevented the study from progressing further. A second trial was conducted too late in the disease process. The results were disappointing.
Another humanized monoclonal antibody, solanezumab, was tested in two large phases of 3 trials. Solanezumab is composed of a collection of humanized anti-Ab monoclonal antibodies. Its effector function is based on the Fc domain of the antibody. It is administered subcutaneously or intravenously.
Active immunotherapies are less expensive than passive immunotherapies. They also have the advantage of target specificity. However, these immunotherapies have also reduced the control over epitope choice. The major safety challenges with immunotherapy are brain microhemorrhage, off-target cross-reactivity, and peripheral sink phenomenon.
There is currently no approved monoclonal antibody for Alzheimer’s disease. However, several active immunotherapy approaches are under investigation in clinical trials. These include AADvac1, AADvac2, and AADvac3.
Active immunotherapies are not without risks. They can have side effects including autoimmune disorders and peripheral sink phenomenon.
Coping strategies
Developing creative coping strategies for Alzheimer’s disease is a must. One should not only do the big three but also seek out individual counseling as well as support from family and friends. One should also keep one’s eyes open for signs of the disease in its early stages. Taking a proactive stance will keep a loved one safe.
As for the small stuff, keep a fire extinguisher within reach and make sure your smoke detector is fresh. Keeping a matchbox out of reach will also go a long way to preventing a house fire. Having an Alzheimer’s disease patient around can be overwhelming at times, but there are ways to minimize the stress.
A clever way to get a loved one to talk about the past is to have a few videos or audio clips of family activities and milestones. The best time to share these stories is during the daytime when the patient is in the mood to recall. A well-chosen soundtrack can also go a long way to reducing stress.
The best coping strategies for Alzheimer’s disease involve a combination of patience, time, and flexibility. It is important to remember that the disease is progressive. This means that the symptoms of the disease will only get worse with time. Fortunately, the Alzheimer’s Association offers a host of resources for family and friends. For example, there is the Safe Return program, which provides an aide-me-me to locate a person with Alzheimer’s disease.
Health Sources:
Health A to Z. (n.d.). HSE.ie. https://www2.hse.ie/az/
U.S. National Library of Medicine. (n.d.). https://www.ncbi.nlm.nih.gov/
Directory Health Topics. (n.d.). https://www.healthline.com/directory/topics
Health A-Z. (2022, April 26). Verywell Health. https://www.verywellhealth.com/health-a-z-4014770
Harvard Health. (2015, November 17). Health A to Z. https://www.health.harvard.edu/health-a-to-z
Health Conditions A-Z Sitemap. (n.d.). EverydayHealth.com. https://www.everydayhealth.com/conditions/
